Orthopedic Surgical Robots Market: as Stryker earns the first FDA-authorised revision feature for any surgical robot while Zimmer Biomet moves to acquire a fully autonomous robotics developer, the two largest orthopedic robotics platforms are placing genuinely different bets on where the category goes next, Stryker deepening clinical capability on its existing Mako installed base, Zimmer Biomet buying its way toward autonomy years ahead of an expected commercial launch, so hospitals selecting a platform today are choosing between near-term capability depth and a longer-term autonomy roadmap that has not yet reached the market.

The global orthopedic surgical robots market size was USD 3.84 Billion in 2025 and is expected to register a revenue CAGR of 9.6% during the forecast period. Market revenue growth is driven by factors such as robotic platform indication expansion extending established systems from knee and hip into shoulder and revision procedures, ambulatory surgical centre adoption broadening the addressable procedure base beyond hospital settings, and spine robotics market consolidation combining platform technology with expanded implant portfolios. The first driving factor is robotic platform indication expansion, as manufacturers extend already-installed systems to additional joint and procedure categories without requiring hospitals to purchase entirely new hardware. Robotic-arm assisted total knee arthroplasty accounts for a substantial share of total 2025 market revenue, reflecting the procedure's continued position as the most established robotic orthopedic application. The second driving factor is ambulatory surgical centre adoption, as robotic platforms increasingly penetrate lower-acuity outpatient settings beyond their historical hospital-only footprint. The third driving factor is spine robotics market consolidation, as platform technology developers combine with implant manufacturers to offer integrated robotic and biologics commercial relationships. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single robotic platform's expanding library of cleared surgical indications converts one hospital capital equipment purchase into a widening set of billable procedure applications, which lets the manufacturer capture additional procedure volume from an already-installed system without requiring the hospital to acquire new hardware for each new indication. Once a hospital has installed a robotic platform for its original cleared indication, each additional indication the manufacturer subsequently clears for that same platform, such as extending from knee arthroplasty into hip revision, converts directly into incremental procedure volume on hardware the hospital has already purchased, so indication expansion compounds platform value without requiring a new capital sales cycle. As a result, demand and revenue share are concentrating around platforms with the broadest cleared indication library on an already-installed hardware base, and the forecast tilts toward manufacturers extending existing systems rather than competitors requiring hospitals to adopt entirely new platforms. For instance, in March 2025, Stryker received FDA 510(k) clearance for its Mako surgical robot to be used in hip revision procedures, the first revision feature authorised by the FDA for any surgical robot, extending the Mako platform's cleared indication library on its already substantial installed hospital base. These are some of the key factors driving revenue growth of the market.

Because a robotic surgical platform represents a substantial capital investment beyond the cost of conventional manual instrumentation, smaller hospitals and ambulatory surgical centres with lower procedure volume face a genuine return-on-investment calculation that can delay or prevent adoption even where surgeons express clinical interest in robotic assistance.

EU MDR Class IIb recertification requirements are a second constraint, since orthopaedic robotic system accessories and disposable instrument components require CE Mark recertification under the transitioned EU Medical Device Regulation framework, adding compliance cost and timeline for manufacturers maintaining European market access.

Surgeon training and workflow adaptation requirements are a third constraint, because transitioning from conventional manual technique to robotic-assisted surgery requires meaningful surgeon training investment, and hospitals face real staffing and scheduling complexity during this transition period that can slow the pace of full robotic platform utilisation even after installation.

These factors substantially limit orthopedic surgical robots market growth over the forecast period.

The clearest driver of demand is robotic platform indication expansion, as manufacturers extend already-installed systems to additional joint and procedure categories without requiring hospitals to purchase entirely new hardware. A hospital that has already invested in a robotic platform for one indication faces a far lower adoption barrier for a newly cleared additional indication on that same hardware than it would for an entirely new platform purchase, so indication expansion converts existing capital investment into incremental procedure volume with minimal additional hospital capital outlay. Robotic-arm assisted total knee arthroplasty accounts for a substantial share of total 2025 market revenue, and in March 2025, Stryker received FDA 510(k) clearance for its Mako surgical robot to be used in hip revision procedures, the first revision feature authorised by the FDA for any surgical robot. The effect on the market is that manufacturer revenue growth increasingly depends on the pace of new indication clearances on existing installed platforms, not solely on new capital placement volume. These are some of the key factors driving revenue growth of the market.

The second driver is ambulatory surgical centre adoption, as robotic platforms increasingly penetrate lower-acuity outpatient settings beyond their historical hospital-only footprint. A growing share of total joint arthroplasty procedures are shifting from hospital inpatient settings to outpatient ambulatory surgical centres given improved surgical technique and patient recovery protocols, so robotic platform manufacturers extending their commercial focus into ASC-appropriate system configurations are following procedure volume to where it is actually moving. The effect on the market is that robotic platform manufacturers increasingly compete on ASC-specific system configuration and pricing, not solely on hospital-focused capital equipment specifications. These are some of the key factors driving revenue growth of the market.

Stryker's March 2025 Mako hip revision clearance is the first revision feature the FDA has authorised for any surgical robot. Zimmer Biomet's move to acquire Monogram Technologies signals a parallel bet on fully autonomous robotics years ahead of an expected commercial launch.

The third driver is spine robotics market consolidation, as platform technology developers combine with implant manufacturers to offer hospitals an integrated robotic and biologics commercial relationship rather than separate vendor engagements. A spine surgery programme's robotic platform decision increasingly influences its implant purchasing relationship, so a combined robotics-and-implant company can offer hospitals a more comprehensive, singularly accountable commercial relationship spanning the full spine surgery episode. In 2025, Zimmer Biomet announced its acquisition of Monogram Technologies, a developer of fully autonomous robotic surgery technology, extending Zimmer Biomet's existing ROSA robotic portfolio toward a longer-term autonomous robotics roadmap alongside its established non-CT-based robotics and navigation offerings. The effect on the market is that competitive positioning in orthopedic robotics increasingly depends on the breadth of a company's combined platform and implant commercial relationship, not robotic technology alone. These are some of the key factors driving revenue growth of the market.

However, the orthopedic surgical robots market faces severe adoption constraints from substantial capital equipment costs limiting adoption among smaller hospitals and ambulatory surgical centres, and EU MDR Class IIb recertification requirements affecting robotic system accessories and disposable components.

Because a robotic surgical platform represents a substantial capital investment beyond the cost of conventional manual instrumentation, smaller hospitals and ambulatory surgical centres with lower procedure volume face a genuine return-on-investment calculation that can delay or prevent adoption even where surgeons express clinical interest in robotic assistance, including newly cleared capabilities like Stryker's Mako hip revision feature.

EU MDR Class IIb recertification requirements compound this, since orthopaedic robotic system accessories and disposable instrument components require CE Mark recertification under the transitioned EU Medical Device Regulation framework, adding compliance cost and timeline for manufacturers maintaining European market access.

Surgeon training and workflow adaptation requirements are the third constraint, because transitioning from conventional manual technique to robotic-assisted surgery requires meaningful surgeon training investment, and hospitals face real staffing and scheduling complexity during this transition period that can slow the pace of full robotic platform utilisation even after installation.

These factors substantially limit orthopedic surgical robots market growth over the forecast period.

Based on platform type, the global orthopedic surgical robots market is segmented into robotic-arm assisted TKA, THA, robotic shoulder arthroplasty, robotic spine systems, and autonomous or semi-autonomous platforms. Robotic-arm assisted TKA holds the largest revenue share, because total knee arthroplasty remains the most established and highest-volume robotic orthopedic application across Stryker's Mako, Zimmer Biomet's ROSA, and Johnson & Johnson's VELYS platforms, which suits a market where the most clinically mature application commands the largest revenue category. Robotic shoulder arthroplasty is expected to register the fastest revenue growth rate in the global orthopedic surgical robots market over the forecast period, driven by both Stryker's and Zimmer Biomet's limited 2025 shoulder application launches expanding toward broader commercial availability in 2026.

Total knee arthroplasty application is expected to account for the largest revenue share in the global orthopedic surgical robots market during the forecast period

Based on application, the global orthopedic surgical robots market is segmented into total knee arthroplasty, total hip arthroplasty, shoulder arthroplasty, spinal fusion and navigation, and revision joint surgery. Total knee arthroplasty holds the largest revenue share, reflecting the procedure's position as the highest-volume joint replacement surgery globally. Revision joint surgery is expected to register the fastest revenue growth rate in the global orthopedic surgical robots market over the forecast period, driven by Stryker's March 2025 Mako hip revision clearance opening the first FDA-authorised robotic revision application.

Hospitals and academic centres end-use is expected to account for the largest revenue share in the global orthopedic surgical robots market during the forecast period

Based on end-use, the global orthopedic surgical robots market is segmented into hospitals and academic centres, ambulatory surgical centres, and specialty orthopedic practices. Hospitals and academic centres hold the largest revenue share, reflecting the concentration of the highest-volume, most complex robotic procedures within hospital-based orthopedic programmes. Ambulatory surgical centres are expected to register the fastest revenue growth rate in the global orthopedic surgical robots market over the forecast period, driven by the continued shift of routine joint arthroplasty procedures from hospital inpatient to outpatient ASC settings.

Based on regional analysis, the orthopedic surgical robots market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA clearance activity and the largest robotic platform installed base globally creates the deepest indication-expansion and capital placement demand, and because Stryker, Zimmer Biomet, and Johnson & Johnson MedTech all maintain their primary commercial presence in the US market. Stryker's Mako hip revision clearance and Zimmer Biomet's Monogram Technologies acquisition specifically reinforce the depth of US-anchored platform innovation. The concentration of FDA regulatory activity in the country also means new robotic indication clearances are typically established in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national markets within Europe. Brainlab's German engineering base and the EU MDR Class IIb transition affecting robotic system accessories both shape the region's competitive and compliance landscape. The result is steady rather than rapid growth, shaped more by EU MDR recertification requirements than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, driven by expanding hospital capital equipment investment and rising joint replacement procedure volume. The region's rapidly scaling hospital infrastructure leaves considerably more room for growth than in the already robotics-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early robotic platform adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision robotic components and specialised electronics that Latin American device distributors depend on, an effect expected to run through 2026 and slow orthopedic surgical robots adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional medical tourism positioning represent the primary investment centres for orthopedic surgical robots adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the surgical robotics infrastructure needed to support advanced platforms at scale.